- LATIN AMERICA
- MIDDLE EAST
- United Kingdom
- United States
- New Zealand
- South Africa
Merck & Co. Common Stock (MRK)
Merck & Co. Corporation is a publicly traded company listed on the New York Stock Exchange under the ticker symbol "MRK" and is a component of the Dow 30 and S&P 500 Index.
As a large and reputable company, Merck is considered by many investors to be a stable and reliable stock to invest in. Like all stocks, the price of Merck stock can be influenced by a variety of factors, including market trends, industry developments, economic conditions, company earnings reports, and more. It's important to conduct thorough research and analysis before making any investment decisions.
Merck & Co. Common Stock Dividend
Merck & Co. pays a quarterly dividend to its shareholders of $0.73 per share effective January, 2023. Merck & Co. has increased its dividend payout every year for the past decade.
The dividend payout history and dividend growth are important factors for investors to consider when evaluating a stock's potential for income. Merck & Co. has a history of paying dividends, and the company has been increasing its dividend payout in recent years.
However, it's important to note that dividend payments are not guaranteed, and can be affected by a range of factors, including the company's financial performance, changes in the regulatory environment, and other economic factors.
MRK price today by TradingView
About Merck & Co. (MRK)
Merck, also known as MSD outside of the United States and Canada, is a multinational pharmaceutical company headquartered in Kenilworth, New Jersey. The company was founded in 1891 and has since grown to become one of the largest pharmaceutical companies in the world, with operations in more than 140 countries and 69,000 employees worldwide.
Merck has been involved in several significant healthcare advancements, including the development of the first measles vaccine, the first statin drug for lowering cholesterol (Mevacor), and the first treatment for HIV/AIDS (Crixivan). In recent years, Merck has also been at the forefront of developing treatments for cancer immunotherapy.
Merck's focus areas include oncology, vaccines, infectious diseases, diabetes, cardiovascular diseases, and animal health. The company has a broad portfolio of products, including blockbuster drugs such as Keytruda (pembrolizumab) for the treatment of various types of cancer, Januvia (sitagliptin) for type 2 diabetes, and Gardasil (human papillomavirus vaccine) for the prevention of certain types of cancer and genital warts. These products have helped to drive the company's growth and profitability.
Merck is known for developing a range of important medicines, including treatments for cancer, HIV, and hepatitis C. The company has also been involved in the development of vaccines, including vaccines for HPV and shingles. In addition to its pharmaceutical business, Merck is also involved in animal health and produces a range of vaccines, pharmaceuticals, and other products for the animal health industry.
Merck has a strong commitment to research and development, investing heavily in the development of new drugs and therapies. The company also has a long history of corporate social responsibility, including efforts to improve access to healthcare in low- and middle-income countries and initiatives to promote sustainability and environmental responsibility.
One of the promising drugs in Merck's pipeline is V114, a 15-valent pneumococcal conjugate vaccine. This vaccine is designed to protect against more strains of pneumococcal bacteria than the current 13-valent vaccine, potentially preventing more cases of pneumococcal disease, which can cause pneumonia, meningitis, and sepsis.
Another promising drug is molnupiravir, an oral antiviral medication being developed for the treatment of COVID-19. Early clinical trial results suggest that molnupiravir can reduce viral load and hasten recovery in patients with mild to moderate COVID-19.
Merck has also been actively involved in global efforts to combat the COVID-19 pandemic. In partnership with Ridgeback Biotherapeutics, the company has developed molnupiravir, and Merck is also collaborating with several other organizations to develop and manufacture vaccines and therapeutics for COVID-19.
Overall, Merck has a long history of innovation and a strong commitment to improving global health. The company's focus on sustainability, corporate social responsibility, and ethical business practices make it a leader in the pharmaceutical industry.
Merck was founded in 1891 by a German immigrant named George Merck in New York City. The company initially imported and distributed chemicals and drugs, but it soon began producing its own pharmaceuticals.
In the early 20th century, Merck developed several important drugs, including the first synthetic vitamin B1 and the first measles vaccine. The company also established a research facility in Rahway, New Jersey, which became one of the leading research centers in the pharmaceutical industry.
During World War II, Merck produced penicillin, a life-saving antibiotic, on a large scale. After the war, the company expanded its research efforts and developed several other groundbreaking drugs, including the first statin drug for lowering cholesterol (Mevacor) and the first treatment for HIV/AIDS (Crixivan).
In 1993, Merck acquired Medco Containment Services, a pharmacy benefit management company, which later became a separate company, Medco Health Solutions. In 2009, Merck merged with Schering-Plough, another pharmaceutical company, to form Merck & Co., Inc. The merger expanded Merck's portfolio of products and increased its global presence.
MRK fundamentals by TradingView